$8,645.99
Description
KEYTRUDA® 25 mg/ml is a humanised monoclonal antibody designed to block the PD-1 receptor, enhancing the immune system’s ability to detect and attack cancer cells. It is widely used in immunotherapy treatments for various types of cancer, including melanoma, lung cancer, and head and neck cancers.
Key features
- PD-1 receptor inhibitor: Blocks the programmed death-1 (PD-1) receptor, restoring T-cell immune response against tumour cells.
- Humanised antibody: Engineered to minimise immune reactions and improve treatment compatibility.
- Versatile cancer treatment: Approved for multiple cancers, offering broad therapeutic applications.
Ingredients
Pembrolizumab (25 mg/ml)
Package content
Single-use vial containing 4 ml solution (100 mg pembrolizumab).
Specifications
- Main Ingredient:
- Manufacturer: Merck
- Drug Class:
- Generic Name: Pembrolizumab
- Package Contents: 25 mg/ml
- Storage Requirements: Cool Temperature (2℃~8℃)
- Main Usage:
Here to help
Questions about ordering, delivery or products? You can email our team here or call now at 1-800-630-9757 and be connected with your dedicated Account Manager
Related Products
RejuvaNAD+
Injectable Medication
$228.79 - $259.99
Powerfill®
Injectable Cosmetic Product
$439.99 - $499.99
$109.11 - $123.99
$109.11 - $123.99
Related Articles
Neuramis Filler – Professional Anti-Aging Injectable
The global dermal filler market has experienced consistent growth, with industry reports valuing it at…
Types of Gel Injections for Knees: Pain Relief Options
Knee pain affects over 1 in 4 adults in the United States, and it’s one…
Rejuran Skin Booster – Advanced Skin Renewal Therapy
Skin aging is an inevitable biological process that is accelerated by environmental stressors, lifestyle factors,…
Nexplanon Implant | Modern Contraception Made Simple
According to the Guttmacher Institute, more than 65% of U.S. women of reproductive age currently…
What Are PDO Threads and How Do They Work?
Thread-based rejuvenation techniques have gained remarkable popularity in aesthetic medicine as a minimally invasive solution…
Hymovis Injection: Relief from Knee Joint Discomfort
Osteoarthritis is one of the major causes of disability worldwide, affecting more than 32.5 million…
Supartz vs Euflexxa – Which Is Best for Joint Pain?
According to the Centers for Disease Control and Prevention (CDC), around 32 million adults in…
Anti-Aging with Peptides for Skin: What to Know
The global anti-aging market is projected to exceed $120 billion by 2030, reflecting a steady…